<?xml version="1.0" encoding="UTF-8"?>
<p>COVID‐19 is the most recent and dramatic pandemic, caused by SARS‐CoV‐2. Registered lethality varies between European countries ranging from 1.5% in Germany to over 10% in Italy [
 <xref rid="ene14277-bib-0001" ref-type="ref">1</xref>]. As in SARS and MERS, pulmonary clinical involvement is most prominent. However, more recently, neurological phenotypes involving central and peripheral nervous system have emerged and are being increasingly recognized, i.e. anosmia, ageusia, necro‐hemorrhagic encephalitis and Guillain–Barré syndrome [
 <xref rid="ene14277-bib-0004" ref-type="ref">4</xref>, 
 <xref rid="ene14277-bib-0005" ref-type="ref">5</xref>, 
 <xref rid="ene14277-bib-0038" ref-type="ref">38</xref>]. So far there are no published human neuropathological findings (Table 
 <xref rid="ene14277-tbl-0001" ref-type="table">1</xref>).
</p>
